Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

Abstract: In example embodiments, a system and method for providing interactive advertisement is provided. In some embodiments, a component causes a video program having an interactive advertisement to be displayed to a user on a display screen. The interactive advertisement includes an enhanced content activator. In response to activation of the enhanced content activator by the user, enhanced advertisement information including at least one trigger is provisioned. The enhanced advertisement information is then caused to be displayed with the video program and the interactive advertisement. A selection by the user of the at least one trigger associated with the enhanced advertisement information is monitored. In response to selection of the at least one trigger, access to further content associated with the enhanced content information is provided.

Abstract: A freight floor having a multilayer construction and that is formed as a composite material, comprising a core layer of carbon-fiber-reinforced and/or glass-fiber-reinforced plastic and a seating layer of a metal alloy, in particular an aluminum alloy.

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

Abstract: The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17A and a peptide tag that binds hyaluronan (HA). The disclosure more specifically relates to specific antibodies and proteins that are IL-17A antagonists (inhibit the activities of IL-17A and IL-17AF) and are capable of inhibiting IL-17A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.

Abstract: The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in viva The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

Abstract: A filling station for filling an envelope is configured to receive a filling material and an envelope. The filling station includes a filling area including at least one filling aid, an envelope feeder configured to receive an envelope and to hold the envelope at least partly at a position outside the filling area, and a transport device configured to move an envelope, which is arranged in the envelope feeder, to the filling aid. The envelope feeder is configured to receive a further envelope during a movement of the preceding envelope from the envelope feeder to the filling aid and/or during filling of the preceding envelope. The transport device is configured to move the further envelope from the envelope feeder to the filling aid once filling of the preceding envelope has been completed and before transporting of the filled envelope out of the filling station has been completed.

Abstract: A freight loading system may include: freight transport devices each with at least one roller for transporting freight items in a transport direction and each sensor for detecting the presence of a freight item, wherein the rollers of at least a first freight transport device are mounted rotationally mobile such that the transport direction of the first freight transport device is adjustable, and a control unit which receives signals from sensors of at least two freight transport devices in order to detect a movement, of a freight item, wherein the control unit is designed to calculate from the signals a relative movement of part of the freight item relative to the first freight transport device and align the at least one roller of the first freight transport device taking into account the relative movement of the part of the freight item.

Abstract: The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

Abstract: A gas turbine membrane seal is disclosed. The gas turbine membrane seal includes a membrane, the membrane configured and arranged to extend from a first gas turbine component to a second gas turbine component and to separate two volumes, and an anti-fretting part configured and arranged to be attached to the first gas turbine component. A face of the anti-fretting part is adjacent to the membrane, and the face of the anti-fretting part is convex. Further embodiments of the gas turbine membrane seal are also described, along with a gas turbine having the gas turbine membrane seal and a retrofitting method.

Abstract: An apparatus for inserting one or more goods into a moving cover includes a cover transport, and at least one filling aid configured to move at least partially into the cover and to be maintained within the cover during at least a part of the movement of the cover.

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

Abstract: A mass flow controller (10) comprises a fluid inlet (15) and at least one first flow meter (11) to measure a first flow rate (F1) and to output a first flow signal (FS1); at least one second flow meter (12) to measure a second flow (F2) rate and to output a second flow signal (FS2); a control device (13) connected to said first and second flow meters (11,12) and configured and arranged to generate a control signal (C); and at least one control valve (14) connected to said control device (13) to control a total flow rate (Fout) through the mass flow controller (10) in response to the control signal (C). The control signal (C) is generated as a function of both the first and second flow signals (FS1,FS2) such that the mass flow controller's (10) sensitivity to perturbations of said inlet pressure is minimized.

Abstract: A lock is proposed for securing containers or similar freight on a cargo bay floor of an aircraft in a vertical direction perpendicular to the cargo bay floor and in a transverse direction perpendicular to a longitudinal direction of the aircraft. The locking element comprises at least one lock attached to a frame for securing containers or similar freight and with a claw in the transverse direction of the aircraft to surround and hold a part section of the container. At least one lock is arranged mobile and fixable in a guide of the frame in order to adapt the spacing of the locks to containers of different sizes.

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

Abstract: An apparatus for inserting one or more goods into a moveable cover includes a goods conveyor configured to move the one or more goods with a first velocity, at least one filling aid, and a cover conveyor configured to move the cover with a second velocity, the second velocity being different from the first velocity.